News
The company’s pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
Source: Maurer M, et al. Abstract L18. Presented at: AAAAI Annual Meeting; Feb. 23-26, 2023; Washington, D.C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback